Rexahn Pharmaceuticals Initiates stage 2 of Phase Ib/IIa Clinical Trial of RX-3117 in Relapsed or Refractory Metastatic Pancreatic Cancer

Sep 12, 2016

Rexahn Pharmaceuticals to Present at 18th Annual Rodman & Renshaw  Global Investment Conference on September 12, 2016

Sep 7, 2016

Rexahn Pharmaceuticals Reports Second Quarter 2016 Financial and Operational Results

Aug 8, 2016

Rexahn Pharmaceuticals Strengthens Leadership Team

Jul 11, 2016

Rexahn Pharmaceuticals Presents Clinical Data for Three Novel Targeted Oncology Programs at the 2016 American Society of Clinical Oncology Annual Meeting

Jun 6, 2016

Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting

May 23, 2016

Rexahn Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update

May 9, 2016

Rexahn Pharmaceuticals Presents Clinical Trial Results for Archexin® at the 2016 American Association for Cancer Research Annual Meeting

Apr 20, 2016

Rexahn Pharmaceuticals to Present at the 2016 American Association for Cancer Research Annual Meeting

Apr 13, 2016

Rexahn Pharmaceuticals Announces Initiation of Phase Ib/IIa Clinical Trial of Its Novel Oral Anti-Cancer Therapeutic RX-3117 in the Treatment of Pancreatic and Bladder Cancer

Mar 29, 2016